People with thyroid eye disease receiving infusions of the insulin-like growth factor-1 receptor veligrotug report improved ...
Mistry described Scp776 as a “designer drug.” She explained that IGF-1 receptors are abundant throughout the body, and IGF-1 ...
A British study examined whether pomegranate polyphenols can influence a hormone closely linked to muscles and regeneration ...
Viridian seeks Priority Review for veligrotug, aiming for a potential mid-2026 commercial launch if approved. Global phase 3 ...
13d
Silver Creek Pharmaceuticals Announces Positive Phase 2 Results for Scp776 in Acute Ischemic Stroke
Key Highlights Scp776 is the first therapy to show clinically meaningful efficacy in late-window stroke patients (treated up to 24 hours after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback